Literature DB >> 848578

Postsynaptic supersensitivity in schizophrenia.

G N Pandey, D L Garver, C Tamminga, S Ericksen, S I Ali, J M Davis.   

Abstract

In the context of the dopamine hypothesis of schizophrenia, the authors examined postsynaptic dopamine (DA) receptor sensitivity in schizophrenic patients by means of a neuroendocrine strategy using the DA receptor agonist apomorphine and growth hormone (GH) release as the measurable postsynaptic event. The activity of platelet adenylate cyclase, an enzyme intimately associated with catecholamine receptor activity, was also studied following stimulation by prostaglandin E1 (PGE1). Patients diagnosed as having acute schizophrenia had significantly higher GH responses and adenylate cyclase activity than normal control subjects and patients diagnosed as having chronic schizophrenia. Chronic schizophrenic patients with and without tardive dyskinesia showed GH responses slightly lower than but not significantly different from those of control groups.

Entities:  

Mesh:

Substances:

Year:  1977        PMID: 848578     DOI: 10.1176/ajp.134.5.518

Source DB:  PubMed          Journal:  Am J Psychiatry        ISSN: 0002-953X            Impact factor:   18.112


  12 in total

Review 1.  G protein-coupled receptor kinase/beta-arrestin systems and drugs of abuse: psychostimulant and opiate studies in knockout mice.

Authors:  Laura M Bohn; Raul R Gainetdinov; Marc G Caron
Journal:  Neuromolecular Med       Date:  2004       Impact factor: 3.843

2.  Cerebrospinal fluid cyclic AMP and acid monoamine metabolites following probenecid: studies in psychiatric patients.

Authors:  M B Bowers; R E Study
Journal:  Psychopharmacology (Berl)       Date:  1979-03-29       Impact factor: 4.530

3.  Platelet alpha-2-receptor binding and adenylate cyclase activity in panic disorder.

Authors:  D S Charney; R B Innis; R S Duman; S W Woods; G R Heninger
Journal:  Psychopharmacology (Berl)       Date:  1989       Impact factor: 4.530

4.  Reduced growth hormone response to apomorphine in schizophrenic patients with poor premorbid social functioning.

Authors:  K L Malas; D P van Kammen; E A de Fraites; G M Brown; P W Gold
Journal:  J Neural Transm       Date:  1987       Impact factor: 3.575

5.  Long-term neuroleptic treatment of chronic schizophrenic patients: clinical and biochemical effects of withdrawal.

Authors:  K J Zander; B Fischer; R Zimmer; M Ackenheil
Journal:  Psychopharmacology (Berl)       Date:  1981       Impact factor: 4.530

Review 6.  Neuroendocrine markers of CNS drug effects.

Authors:  E C Johnstone; I N Ferrier
Journal:  Br J Clin Pharmacol       Date:  1980-07       Impact factor: 4.335

7.  Effects of indomethacin on plasma homovanillic acid concentration in normal subjects: a study of prostaglandin-dopamine interactions.

Authors:  R S Kahn; M Davidson; P Kanof; R T McQueeney; R R Singh; K L Davis
Journal:  Psychopharmacology (Berl)       Date:  1991       Impact factor: 4.530

8.  Dopamine and non-dopamine psychoses.

Authors:  D L Garver; F Zemlan; J Hirschowitz; R Hitzemann; M L Mavroidis
Journal:  Psychopharmacology (Berl)       Date:  1984       Impact factor: 4.530

9.  Neuroendocrine effects of apomorphine in chronic schizophrenic patients under long-term neuroleptic therapy and after drug withdrawal: relations to psychopathology and tardive dyskinesia.

Authors:  F Müller-Spahn; M Ackenheil; M Albus; G May; D Naber; D Welter; K Zander
Journal:  Psychopharmacology (Berl)       Date:  1984       Impact factor: 4.530

10.  Effect of domperidone on apomorphine-induced growth hormone secretion in normal men.

Authors:  S Lal; N P Nair; H L Iskandar; P Etienne; P L Wood; G Schwartz; H Guyda
Journal:  J Neural Transm       Date:  1982       Impact factor: 3.575

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.